Programme Thesis
The NIH SBIR Phase IIB Strategic Breakthrough Award (R44) funds small businesses to accelerate the development and commercialization of high-impact biomedical technologies that have already demonstrated proof of concept, with a focus on products addressing significant unmet medical needs. It exists to bridge the gap between Phase II SBIR-funded prototypes and market entry, providing up to $3 million in additional funding for late-stage development, clinical trials, and regulatory approval.
Selection Criteria
1. Overall Impact (scored 1-9): Potential to improve human health and advance science. 2. Significance: Does the project address a critical problem? 3. Innovation: Novelty of approach relative to existing alternatives. 4. Approach: Feasibility of research plan, milestones, and commercialization strategy. 5. Investigators: Qualifications and track record of the PD/PI and team. 6. Environment: Adequacy of facilities, resources, and small business infrastructure. 7. Commercialization Plan: Strength of market analysis, regulatory pathway, and business model. 8. SBIR-specific: U.S. small business eligibility (majority U.S.-owned/controlled, PI primarily employed by small business, ≤500 employees).
Past Winners / Cohort Profiles
Typical winners are U.S.-based small biotech or medtech companies with a strong scientific founder, often a PhD/MD with prior SBIR Phase I/II funding. Examples include companies developing novel therapeutics, diagnostics, or medical devices (e.g., brain-computer interfaces, addiction treatments). Named examples not found on this page, but common archetypes: a startup with a validated prototype, a clear regulatory path (FDA), and a team including business and clinical expertise.
Ideal Candidate Fingerprint
A U.S.-registered small business (e.g., LLC or C-corp) with a majority U.S.-based team, a PI who is a U.S. citizen or permanent resident, and a product that has completed Phase II SBIR milestones (e.g., preclinical validation, early clinical data). The ideal applicant has a strong commercialization plan, a clear unmet need, and a multidisciplinary team including regulatory, clinical, and business expertise.
Recommended Framing
Eniola should partner with a U.S.-based small business (e.g., a neurotech or addiction therapeutics startup) or establish a U.S. subsidiary of ZYCO to become eligible. His CCT model and IMPRINT/TOPOLOGIX platforms are strong assets for a Phase IIB award targeting addiction treatment or cardiotoxicity screening. He should emphasize the 85.8% reduction in encoding probability, the provisional patent, and endorsements from Berridge/Gershman to demonstrate scientific credibility, while framing the work as a late-stage clinical trial or regulatory submission for a digital therapeutic or screening tool.
Watch Out
1. U.S. small business eligibility: Eniola is a Nigerian citizen based in Lagos, not a U.S. resident, and his company ZYCO is likely not U.S.-based. He must form a U.S. subsidiary or partner with a U.S. small business. 2. PI primary employment: The PI must be primarily employed by the small business (>50% time). Eniola's current employment at Synthcare may conflict. 3. No prior SBIR Phase I/II: This award requires prior SBIR Phase II funding; Eniola has none. He would need to first apply for Phase I or Phase II, or find a partner with existing SBIR funding. 4. Clinical trial optional: If he proposes a clinical trial, he needs U.S. regulatory and clinical infrastructure.